1. Absorption, distribution, metabolism and excretion of an isocitrate dehydrogenase-2 inhibitor enasidenib in rats and humans. (1st February 2019) Authors: Tong, Zeen; Atsriku, Christian; Yerramilli, Usha; Wang, Xiaomin; Li, Yan; Reyes, Josephine; Fan, Bin; Yang, Hua; Hoffmann, Matthew; Surapaneni, Sekhar Journal: Xenobiotica Issue: Volume 49:Number 2(2019:Feb.) Page Start: 200 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Absorption, distribution, metabolism, and excretion of mTOR kinase inhibitor CC-223 in rats, dogs, and humans. (2nd January 2019) Authors: Tong, Zeen; Atsriku, Christian; Yerramilli, Usha; Wang, Xiaomin; Nissel, Jim; Li, Yan; Surapaneni, Sekhar Journal: Xenobiotica Issue: Volume 49:Number 1(2019:Jan.) Page Start: 43 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Assessement of metabolism and excretion of CC-223 in healthy volunteers using accelerator mass spectrometry. Issue 1 (January 2017) Authors: Tong, Zeen; Atsriku, Christian; Yerramilli, Usha; Wang, Xiaomin; Li, Yan; Surapaneni, Sekhar Journal: Drug metabolism and pharmacokinetics Issue: Volume 32:Issue 1(2017)Supplement Page Start: S79 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Assessment of drug-drug interactions of CC-90001, a potent and selective inhibitor of c-Jun N-terminal kinase. (2nd December 2021) Authors: Tong, Zeen; Gaudy, Allison; Tatosian, Daniel; Ramirez-Valle, Francisco; Liu, Hong; Chen, Jian; Hoffmann, Matthew; Surapaneni, Sekhar Journal: Xenobiotica Issue: Volume 51:Number 12(2021) Page Start: 1416 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Assessment of drug–drug interaction potential and PBPK modeling of CC-223, a potent inhibitor of the mammalian target of rapamycin kinase. (2nd January 2019) Authors: Tong, Zeen; Narayanan, Rangaraj; Atsriku, Christian; Nissel, Jim; Li, Yan; Liu, Hong; Wang, Xiaomin; Surapaneni, Sekhar Journal: Xenobiotica Issue: Volume 49:Number 1(2019:Jan.) Page Start: 54 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Assessment of interaction with nucleosidal transporters between enasidenib and azacytidine. Issue 1 (January 2019) Authors: Yerramilli, Usha; Hoffmann, Matthew; Surapaneni, Sekhar; Tong, Zeen Journal: Drug metabolism and pharmacokinetics Issue: Volume 34:Issue 1(2019)Supplement Page Start: S42 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Assessment of Transporter‐Mediated Drug Interactions for Enasidenib Based on a Cocktail Study in Patients With Relapse or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome. (27th October 2021) Authors: Cheng, Yiming; Wang, Xiaomin; Tong, Zeen; Reyes, Josephine; Carayannopoulos, Leon; Zhou, Simon; Li, Yan Journal: Journal of clinical pharmacology Issue: Volume 62:Number 4(2022) Page Start: 494 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Development of an enhanced formulation to minimize pharmacokinetic variabilities of a weakly basic drug compound. (21st April 2022) Authors: Pu, Yu (Elaine); Menger, Robert; Tong, Zeen; Gaebele, Tracy Journal: Pharmaceutical development and technology Issue: Volume 27:Number 4(2022) Page Start: 406 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. In vitro inhibition of human nucleoside transporters and uptake of azacitidine by an isocitrate dehydrogenase-2 inhibitor enasidenib and its metabolite AGI-16903. (3rd October 2019) Authors: Tong, Zeen; Yerramilli, Usha; Yao, Sylvia; Young, James D.; Hoffmann, Matthew; Surapaneni, Sekhar Journal: Xenobiotica Issue: Volume 49:Number 10(2019:Oct.) Page Start: 1229 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Initial testing (stage 1) of the tubulin binding agent nanoparticle albumin‐bound (nab) paclitaxel (Abraxane®) by the Pediatric Preclinical Testing Program (PPTP). Issue 7 (23rd March 2015) Authors: Houghton, Peter J.; Kurmasheva, Raushan T.; Kolb, E. Anders; Gorlick, Richard; Maris, John M.; Wu, Jianrong; Tong, Zeen; Arnold, Michael A.; Chatterjee, Moumita; Williams, Terence M.; Smith, Malcolm A. Journal: Pediatric blood & cancer Issue: Volume 62:Issue 7(2015:Jul.) Page Start: 1214 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗